Institutional Biosafety Committee (IBC) Meeting Minutes

Institution:	**Wake Forest University School of Medicine**			
Meeting Date and Time:	March 18th 2026			
Meeting Type:	Online via Microsoft Teams			
	Name	**Role and Department**	**Attendance**	
IBC Members Present:	Frank Marini, PhD	IBC Chair, WFIRM	☒ Present	☐ Absent
	Anthony Blaeser, PhD	IBC Vice Chair Musculoskeletal Department	☒ Present	☐ Absent
	Samuel Centanni, PhD	Voting Member, Translational Neuroscience	☒ Present	☐ Absent
	Ji Hyun Kim, PhD	Voting Member, WFIRM	☐ Present	☒ Absent
	Elizabeth Palavecino, MD	Voting Member, Pathology	☒ Present	☐ Absent
	David Ornelles, PhD	Voting Member, Microbiology and Immunology	☐ Present	☒ Absent
	Marlena Westcott, PhD	Voting Member, Microbiology and Immunology	☐ Present	☒ Absent
	Brian Strittmatter, PharmD, MSCR	Voting Member, Pharmacy Clinical Trial Services, Pharmacy Manager	☒ Present	☐ Absent
	Patrick McNutt, PhD	Voting Member, WFIRM,	☒ Present	☐ Absent
	Linda Metheny-Barlow, PhD	Voting Member, Radiation Oncology	☒ Present	☐ Absent
	Swapan Das, PhD, MSc	Voting Member, IM. Endocrinology & Metabolism	☒ Present	☐ Absent
	Caryn Gee Morse, MD, PhD	Voting Member, IM, Infectious Diseases	☐ Present	☒ Absent
	Robert Hampson, PhD	Voting Member, WFIRM	☒ Present	☐ Absent
	Farah Mougeot, PhD, MS	Voting Member, Translational Research – Oral Medicine	☐ Present	☒ Absent
	Kimberly Woodward, MD, MPH	Voting Member, Pathology	☒ Present	☐ Absent
	Paris Charilaou, MD, FACP	Voting Member, Gastroenterology and Hepatology	☒ Present	☐ Absent
	Yuming Jiang, MD, PhD	Voting Member, Radiation Oncology	☒ Present	☐ Absent

	Dan Hurley	Local Non-Affiliated Community Member (Charlotte)	☐ Present	☒ Absent
	Jeanette Bennett	Community Member (Charlotte)	☐ Present	☒ Absent
	Kara Milton	Community Member (Winston Salem)	☐ Present	☒ Absent
	Adam Bray	Community Member (Winston Salem)	☒ Present	☐ Absent
	Christpher Ohl, MD	Voting Member, IM, Infectious Diseases (Ad-Hoc)	☐ Present	☒ Absent
	Scott Gamble, DVM	Voting Member, Animal Expert	☒ Present	☐ Absent
	Lisa Colvin	Voting Contact, IBC Administrator	☒ Present	☐ Absent
	Emylee Pedersen	Voting Contact, IBC Administrator	☒ Present	☐ Absent
	Jessica Baker	Voting Member, IACUC Representative	☒ Present	☐ Absent
	Katy Heide	Voting Member, EHS, Environmental Compliance	☐ Present	☒ Absent
	Ex Officio W/O Vote			
	Suzy Mounsey	Animal Resources Program	☐ Present	☒ Absent
	Gaye Hodges	Animal Resources Program	☐ Present	☒ Absent
	Stephen Fisenne	WFU Representative	☐ Present	☒ Absent
	Morgan Lawson	Environmental Health & Safety	☒ Present	☐ Absent
	Jennifer Williams	Environmental Health & Safety	☒ Present	☐ Absent
	Joseph Kim	AHWFB Teammate Health	☐ Present	☒ Absent
Quorum:	Yes			
Call to Order:	12:34			
Conflicts of Interest:	None			
Review and Approval of Previous Meeting Minutes:	Motion to approve February minutes posed by Dr. Marini second by Dr. McNutt			
Review of Prior Meeting Business (if applicable):	None			
New IBC Registrations and Modifications for Review				
PI Name:	Du, Heng			
Registration Number:	B26-W-016			
Biosafety Protocol Title:	Metabolism and neuroinflammation in Alzheimer's disease			

Project Overview:	Behavior, electrophysiology, neuropathology, and biochemistry experiments will be performed on rodent models to examine the impact of [redacted], metabolic dysregulation and neuroinflammation on Alzheimer's Disease.
Applicable NIH Guidelines:	Section III-D-3
Agent Description: e.g. virulence, pathogenicity, environmental stability	[redacted].
Types of Manipulations:	DNA/RNA sequences sources and packaged into vector by commercial vendor
Source of nucleic (DNA/RNA) sequences: e.g. species	DNA/RNA sequences sources and packaged into vector by commercial vendor.
Nature of nucleic acid sequences: e.g. structural gene, oncogene	Metabolic gene expression
Host(s) and Vector(s):	Host: Various commercially purchased cell lines. Vector: [redacted]
Will a transgene be expressed? If so, what is the function of the protein that will be produced?	Expression of [redacted] cells and organoids
Risk Assessment Discussion Points:	Protocol needs to be divided into three separate protocols so animal biosafety level can be appropriately evaluated.
Training:	• Initial Biosafety Training • Animal Biosafety (AALAS Biosafety course certificate can be submitted in lieu of CITI training for animal work) • NIH Recombinant DNA Guidelines • Emergency and Incident Response to Biohazard Spills and Releases • OSHA Bloodborne Pathogens
Occupational Health Review (if applicable):	NA
Biosafety Level: Animal Biosafety Level:	BSL-2
IBC Vote:	Approve pending protocol modifications at BSL 2
New IBC Registrations and Modifications for Review	
PI Name:	Ferreri, Christopher
Registration Number:	B26-CT-C-006
Biosafety Protocol Title:	mRNA-2808-P101: A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants with Relapsed or Refractory Multiple Myeloma
Project Overview:	First In Human (FIH), Phase 1/2, open-label, multicenter, dose-escalation study of participants with Relapsed/Refractory Multiple Myeloma. The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 and to determine the RP2D(s) in participants with refractory or relapsed multiple myeloma

Applicable NIH Guidelines:	Section III-C-I
Agent Description: e.g. virulence, pathogenicity, environmental stability	[redacted] designed for participants with MM. mRNA-2808 is comprised of [redacted]. These mRNAs encode [redacted] promoting T cell-mediated cytotoxicity of tumor cells
Types of Manipulations:	Manipulations performed by study agent manufacturer.
Source of nucleic (DNA/RNA) sequences: e.g. species	N/A
Nature of nucleic acid sequences: e.g. structural gene, oncogene	T-Cell activation
Host(s) and Vector(s):	Host: [redacted] Vector: mRNA 2808
Will a transgene be expressed? If so, what is the function of the protein that will be produced?	anti-GPRC5D HC×anti-CD3, anti-FcRH5 HC×anti-CD3, anti-BCMA HC×anti-CD3, and an anti-HSA common LC×anti-CD3
Risk Assessment Discussion Points:	None
Training:	Training provided by study sponsor.
Occupational Health Review (if applicable):	None
Biosafety Level: **Animal Biosafety Level:**	BSL 2
IBC Vote:	Approve at BSL 2
New IBC Registrations and Modifications for Review	
PI Name:	Luo, Guangxiang
Registration Number:	12.2023.MicroImm.11000.773.01
Biosafety Protocol Title:	Hepatitis B virus and its interactions with host and HIV
Project Overview:	TBD
Applicable NIH Guidelines:	NA
Agent Description: e.g. virulence, pathogenicity, environmental stability	NA
Types of Manipulations:	NA

Source of nucleic (DNA/RNA) sequences: e.g. species	NA
Nature of nucleic acid sequences: e.g. structural gene, oncogene	NA
Host(s) and Vector(s):	NA
Will a transgene be expressed? If so, what is the function of the protein that will be produced?	NA
Risk Assessment Discussion Points:	[redacted]. [redacted] needs to more clearly describe the use of HDV in experiment.
Training:	• Initial Biosafety Training • Animal Biosafety (AALAS Biosafety course certificate can be submitted in lieu of CITI training for animal work) • NIH Recombinant DNA Guidelines • Emergency and Incident Response to Biohazard Spills and Releases • OSHA Bloodborne Pathogens
Occupational Health Review (if applicable):	None
Biosafety Level: **Animal Biosafety Level:**	BSL/ABSL 2
IBC Vote:	Tabled
3 Year Resubmission	
PI Name:	Asmis, Reto
Biosafety Protocol Number:	B26-W-001
Biosafety Protocol Title:	[redacted] in Adipose Tissue Inflammation and the Onset of Obesity
Project Overview:	Evaluate the hypothesis that [redacted]
Applicable NIH Guidelines:	Section III-D-3 Section III-D-4 Section III-E-3
Agent Description: e.g. virulence, pathogenicity, environmental stability	Previously generated [redacted] vector carrying [redacted] construct.

Types of Manipulations:	Gene modifying [redacted].
Source of nucleic (DNA/RNA) sequences: e.g. species	All genetic material sourced from commercial vendor.
Nature of nucleic acid sequences: e.g. structural gene, oncogene	Protein expression
Host(s) and Vector(s):	Host: [redacted] Vector: [redacted]
Will a transgene be expressed? If so, what is the function of the protein that will be produced?	[redacted] expression
Risk Assessment Discussion Points:	Protocol still needs additional clarification and exact explanation of the recombinant DNA work that is being done.
Training:	• Annual Biosafety retraining • Animal Biosafety (AALAS Biosafety course certificate can be submitted in lieu of CITI training for animal work) • NIH Recombinant DNA Guidelines • Emergency and Incident Response to Biohazard Spills and Releases • OSHA Bloodborne Pathogens
Occupational Health Review (if applicable):	None
Biosafety Level: **Animal Biosafety Level:**	BSL 2
IBC Vote:	Approved pending modifications at BSL 2
3 Year Resubmission Review	
PI Name:	Lu, Baisong
Biosafety Protocol Number:	B26-W-017
Biosafety Protocol Title:	[redacted] particles for genome editing
Project Overview:	Development of viral vectors for future treatment of genetic diseases such as Dent Disease and Duchenne muscular dystrophy.
Applicable NIH Guidelines:	Section III-D-4 Section III-E-3 Section III-E
Agent Description: e.g. virulence, pathogenicity, environmental stability	[redacted] particles, [redacted].
Types of Manipulations:	Expansion of plasmid DNA by [redacted] Expanded plasmid is packaged in [redacted] system using [redacted] vectors,

	exosomes, and [redacted] particles and delivered to [redacted] cells or other cell lines
Source of nucleic (DNA/RNA) sequences: e.g. species	[redacted]
Nature of nucleic acid sequences: e.g. structural gene, oncogene	Protein Expression
Host(s) and Vector(s):	Hosts: [redacted] Vectors: [redacted]
Will a transgene be expressed? If so, what is the function of the protein that will be produced?	[redacted] expression
Risk Assessment Discussion Points:	Protocol needs to describe testing for replication competence if building vectors in the lab.
Training:	• Initial Biosafety Training • Animal Biosafety (AALAS Biosafety course certificate can be submitted in lieu of CITI training for animal work) • NIH Recombinant DNA Guidelines • Emergency and Incident Response to Biohazard Spills and Releases • OSHA Bloodborne Pathogens
Occupational Health Review (if applicable):	None
Biosafety Level: **Animal Biosafety Level:**	BSL 2/ ABSL 2
IBC Vote:	Approved pending modifications at BSL 2/ABSL 2
Other	
New Business:	Annual fume hood face velocity certification taking place during the month of March.
Review of Incidents:	None
Lab Assessments Update:	NA
IBC Training	NA
Public Comments	None
Adjournment	Meeting Adjourned at 1:23